241 blood cancer drugs are in the pipeline

04/29/2013 | Drug Store News

The pipeline of blood cancer treatments in clinical testing or being reviewed by the FDA includes 241 drugs, according to the Pharmaceutical Research and Manufacturers of America. Ninety-eight of the drugs are being developed for the treatment of lymphoma, while 97 are being developed for leukemia, 52 for multiple myeloma and 24 for other cancers of the bone marrow, blood and lymph nodes.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA